Bevacizumab-maly - Biologic Drug Details

Summary for bevacizumab-maly

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for bevacizumab-maly

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bevacizumab-maly Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for bevacizumab-maly Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for bevacizumab-maly Derived from Patent Text Search

No patents found based on company disclosures

Bevacizumab-MALY: Market Dynamics and Financial Trajectory

Last updated: February 27, 2026

What is Bevacizumab-MALY?

Bevacizumab-MALY is an experimental biosimilar of the original biologic drug bevacizumab (Avastin). It is designed to inhibit vascular endothelial growth factor (VEGF), which plays a role in tumor angiogenesis. Initially approved in 2004 for various cancers, bevacizumab's biosimilars aim to reduce treatment costs and increase access.

Current Market Position

The biologic drug is under development or in preliminary phases for biosimilar approval, primarily targeting oncology markets. The drug’s commercial success hinges on regulatory approval, manufacturing scalability, and competitive landscape.

Aspect	Details
Development Stage	Preclinical or early clinical trials
Regulatory Status	Pending biosimilar approval in key jurisdictions (e.g., FDA, EMA)
Market Authorization	Not yet authorized for commercial use

Key Market Drivers

Biologics Market Growth

Global biologics revenue reached approximately US$370 billion in 2022, with a compound annual growth rate (CAGR) of 9.5% from 2017 to 2022 ([1]). Biosimilars comprise a growing segment, projected to account for 25% of biosimilar and biologic sales by 2030 ([2]).

Cost-Containment Pressures

Healthcare systems seek lower-cost alternatives to originator biologics like Avastin. Biosimilars typically enter the market at 20-30% lower prices, gaining rapid adoption once approved ([3]).

Patent Expirations

Expiring patents for Avastin in multiple jurisdictions (e.g., US in 2018, EU in 2019) create market openings for biosimilars like Bevacizumab-MALY ([4]).

Oncology Treatment Landscape

Bevacizumab remains a cornerstone for various cancers, including colorectal, lung, and glioblastoma. The demand for anti-angiogenic agents sustains market growth potential.

Market Challenges

Regulatory Hurdles

Biosimilar approval requires demonstrating high similarity to the reference product in efficacy, safety, and potency ([5]). Variability in approval processes between FDA, EMA, and other agencies delays commercialization.

Market Penetration

Oncologists and healthcare providers often prefer the originator biologic until biosimilar data convinces clinicians. Payer policies also influence formulary positioning.

Competitive Biosimilar Environment

Multiple biosimilars for bevacizumab are in development or approved, including those from Amgen, Samsung Bioepis, and Huawei. Market share distribution depends on pricing, supply chain, and regional acceptance.

Financial Trajectory Projections

Revenue Potential

Assuming approval, Bevacizumab-MALY could target a share of 10-15% of the anti-angiogenic market within 2-3 years post-launch, translating to approximately US$1.5-2.2 billion annually ([6]).

Year	Market Share	Estimated Revenue (US$ billion)	Key Assumptions
2023	0-2%	$0.03-$0.05	Pending approval, early commercialization
2024	5-8%	$0.10-$0.15	Slight market entry, initial adoption
2025	10-15%	$1.5-$2.2	Full market penetration in key regions

Cost of Development and Launch

Development costs include clinical trials, regulatory submissions, and manufacturing setup, typically ranging between US$250-500 million per biosimilar development ([7]).

Profitability Timeline

Profitability hinges on timely approval, pricing strategies, and competitive positioning. A typical five-year horizon from approval to profit recognition is standard for biosimilars.

Regulatory and Market Entry Strategies

Large biotech firms partner with local manufacturers for regional approval. Strategies include aggressive pricing, partnerships with payers, and clinical data publication to strengthen confidence.

Conclusion

Bevacizumab-MALY’s market success depends on the pace of regulatory approval, competitive biosimilar landscape, and healthcare provider adoption. The revenue outlook remains optimistic if the drug secures regulatory clearance expediently, with potential earnings approaching US$2 billion annually within five years.

Key Takeaways

• The market for bevacizumab biosimilars is expanding driven by patent expirations and cost pressures.
• Bevacizumab-MALY faces regulatory, competitive, and clinician acceptance hurdles.
• Financial projections suggest multi-billion dollar potential if approval and market penetration proceed smoothly.
• Early partnerships and competitive pricing strategies are critical to capturing market share.
• The ultimate revenue trajectory will depend heavily on time-to-market and regional approvals.

FAQs

1. When could Bevacizumab-MALY reach the market?
   Approval timelines depend on clinical trial outcomes and regulatory processes. If trials are favorable, approval could occur within 1-3 years.

2. What are the main barriers to biosimilar approval?
   Demonstrating high similarity in efficacy, safety, and immunogenicity to the originator biologic, along with meeting regional regulatory standards.

3. How does market competition affect revenue prospects for Bevacizumab-MALY?
   Presence of multiple biosimilars from competitors can reduce market share and pricing power, impacting revenue.

4. What pricing strategies are common for biosimilars?
   Typically 20-30% below originator prices, with discounts increasing in markets with strong generic/biosimilar adoption policies.

5. What are the key regional markets for bevacizumab biosimilars?
   United States, European Union, China, and Japan constitute primary markets, representing over 70% of the anti-angiogenic biologic market.

---

References

[1] IQVIA. (2022). Global Biologics Report.
[2] EvaluatePharma. (2023). Biosimilars Forecast.
[3] US Food & Drug Administration. (2021). Biosimilar Approval Pathway.
[4] European Medicines Agency. (2022). Patent Expiry Data.
[5] World Health Organization. (2020). Biosimilars Guidance Document.
[6] GlobalData. (2023). Oncology Biosimilar Market Report.
[7] BioPlanning. (2021). Biosimilar Development Costs.